indolent NHL and MCL
Haematology · 2015–2015
1decision
1medicine
1carried consumer input
10individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bendamustine First-line treatment of previously untreated Stage III–IV indolent CD20-positive Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma in combination with rituximab,… | Mar 2015 | Deferred | 10 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.